FDA accepts CMC plan for lead Bionovo drug

The FDA has accepted Bionovo's chemistry, manufacturing and controls (CMC) plan for its lead drug candidate, Menerba. With the FDA's approval of the company's CMC plan, Bionovo is now in final discussions with the agency to complete the design of the Phase III pivotal trials in the U.S. Bionovo release

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.